Navigation Links
Official Signing Ceremony for WIBP Strategic Alliance

MONTREAL, June 5 /PRNewswire-FirstCall/ -- ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") announced today that the official signing ceremony for the strategic alliance concluded earlier this year with the Wuhan Institute of Biological Products ("WIBP") a subsidiary of China National Biotec Group ("CNBG") was held on Wednesday, June 4, 2008 at CNBG's Beijing location.

Present at the signing were CNBG's President and Chief Executive Officer Ms. Lifeng Wang, WIBP's Director Dr. Xiaoming Yang, ProMetic's President and Chief Executive Officer Mr. Pierre Laurin as well as several officials from the CNBG and WIBP organizations. Additional information is available on CNBG's web site at and on WIBP's web site at

More about Wuhan Institute of Biological Products

WIBP ( or, located in Wuhan, China. is one of the subsidiaries of CNBG, has over 50 years experience in the fields of biomedical research and product development; historically strong in R&D, WIBP is the only institute certified by state to offer doctoral program among six Institute of Biological Products in CNBG. Today, WIBP has more than 1,000 employees, and major products include two dozen vaccines and plasma derivatives currently marketed throughout the China.

More about China National Biotec Group

CNBG ( or, headquartered in Beijing, China, is a state-owned enterprise and the largest biotech company in China dedicated to discover, develop, manufacture and market a broad range of human health products, including vaccines, blood derivatives, biopharmaceuticals, diagnostic reagents and others. With more than 9,000 employees and revenues of 421 million USD in 2006, CNBG is the largest producer of vaccines and blood derivatives in China, enjoying more than 80% and 30% market share respectively. The company consists of 6 Institute of Biological Products and an international trading company.

About ProMetic Life Sciences Inc.

ProMetic ( is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand(TM) technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and business development activities in the U.S., Europe, Asia and in the Middle-East.

SOURCE ProMetic Life Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SURGEX(TM) Becomes the Official Sports Nutrition Drink of Former NBA Player Dee Brown and his Edge Basketball Training Facility
2. Interleukin Genetics Welcomes the Signing of the Genetic Information Nondiscrimination Act (GINA)
3. WaferGen Announces Signing of Two Private Placements
4. Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement
5. Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
6. CTDC Attends the Inauguration Ceremony of Thin Film A-Si Manufacturing Line in Changzhou, China
7. CTDC Holds a Ribbon Cutting Ceremony to Showcase First SnO2 Production Line
8. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
9. Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs
10. AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
11. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont Pioneer and recently ... have entered into a multiyear collaboration to identify and characterize novel CRISPR-Cas nucleases. ... for gene editing across all applications. , Under the terms of the agreement, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the first-ever genomics analysis platform specifically designed for life science researchers to ... of pioneering researcher Rosalind Franklin, who made a major contribution to the ...
(Date:10/11/2017)... CA, USA (PRWEB) , ... October 11, 2017 , ... ... to take place on 7th and 8th June 2018 in San Francisco, CA. The ... influencers as well as several distinguished CEOs, board directors and government officials from around ...
(Date:10/11/2017)... ... , ... Disappearing forests and increased emissions are the main causes of the ... Especially those living in larger cities are affected by air pollution related diseases. , ... pollution-affected countries globally - decided to take action. , “I knew I had to ...
Breaking Biology Technology:
(Date:8/15/2017)... 2017   ivWatch LLC , a medical device company focused ... announced receipt of its ISO 13485 Certification, the global standard for ... for Standardization (ISO®). ... 400 Continuous Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, ...
(Date:6/14/2017)... June 15, 2017  IBM (NYSE: IBM ) is introducing ... event dedicated to developing collaboration between startups and global businesses, ... 15-17. During the event, nine startups will showcase the solutions ... various industries. France ... market, with a 30 percent increase in the number of ...
(Date:5/6/2017)... 2017 RAM Group , Singaporean ... breakthrough in biometric authentication based on a ... to perform biometric authentication. These new sensors are based ... by Ram Group and its partners. This sensor will ... chains and security. Ram Group is a next ...
Breaking Biology News(10 mins):